MNMD
Mind Medicine (MindMed) Inc.
NASDAQ · Healthcare · Biotechnology · CA
$20.69
+0.44%Price chart
Jul 14Jul 17Jul 22Jul 27Jul 30Aug 4Aug 7Aug 12
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
Market Cap
$1.85B
MomentumView details →
1D Return
+0.44%
YTD Return
+219.57%
RSI (14)
50.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
Market Cap
$1.85B
RSI (14)
50.9
MomentumView details →
1D Return
+0.44%
YTD Return
+219.57%
SummaryUpdated Dec 1, 2025
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Vancouver, Canada. The company went public in 2016 and focuses on developing novel therapeutic treatments for brain health disorders including psychiatry, addiction, pain, and neurology. MindMed is at the forefront of psychedelic medicine research, developing treatments based on compounds like LSD and MDMA that have shown promise in addressing mental health conditions that affect millions of people worldwide.
Similar companies
Latest newsMore news →
Definium Therapeutics issued inducement stock options to two newly hired non-executive employees to purchase an aggregate of 32,900 common shares, with effective grant dates of August 17, 2026.18d agoDefinium Therapeutics announced that its LSD therapy DT120 significantly eased anxiety in a late-stage Phase 3 trial for generalized anxiety disorder.23d ago